Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Track-And-Trace: With Deadline A Year Away, Some Lessons From Early Adopters

Executive Summary

EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.

You may also be interested in...



As HHS Secretary, Nominee Burwell Would Preside Over ACA Policy Revisions

OMB Director Sylvia Burwell is nominated to take the helm at HHS, where she would manage future evolutions in the exchange plans, including possible changes to drug coverage policies that would be effective in 2016.

As HHS Secretary, Nominee Burwell Would Preside Over ACA Policy Revisions

OMB Director Sylvia Burwell is nominated to take the helm at HHS, where she would manage future evolutions in the exchange plans, including possible changes to drug coverage policies that would be effective in 2016.

European Notebook: IPO Fever Comes To Europe; EMA Plans Adaptive Licensing Pilot Project

Pharmaceutical and biotech companies in Europe take heart from IPOs and new governmental schemes to improve patients’ early access to innovative medicines, while fresh calls are made for an integrated, over-arching European industrial strategy for the life sciences sector.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS055910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel